Table 2.
Groups | IgG1 | IgG2 | IgG3 | IgG4 |
---|---|---|---|---|
GLURP | ||||
CZS | 40/46* (87%) | 10/46 (21,7%) | 33/46* (71,7%) | 10/46 (21,7%) |
ML | 30/34** (88,2%) | 7/34 (20,6%) | 12/34 (35,3%) | 6/34 (21,7%) |
GJ | 23/24*** (95,8%) | 1/24 (4,2%) | 9/24 (37,5%) | 2/24 (8,3%) |
MSP-3 | ||||
CZS | 28/31**** (90,3%) | 0/31 (0%) | 8/31 (25,8%) | 0/31 (0%) |
ML | 6/7 | 0/7 | 3/7 | 0/7 |
GJ | 5/5 | 1/5 | 4/5 | 2/5 |
Pfs48/45 | ||||
CZS | 2/2 | 0/2 | 0/2 | 1/2 |
ML | 2/2 | 0/2 | 0/2 | 0/2 |
GJ | 3/7 | 1/7 | 3/7 | 4/7 |
*P < 0.0001, IgG1 and IgG3 versus IgG2 and IgG4. **P < 0.0001, IgG1 versus IgG2, IgG3 and IgG4. ***P < 0.0001, IgG1 versus IgG2 and IgG4. ****P < 0.0001, IgG1 versus IgG2, IgG3 and IgG4. Only the IgG positive samples were tested for subclasses. Prevalence of responders within and between Groups were compared by Chi-squared tests